TY  - JOUR
AU  - Rodríguez-Serrano, Fernando
AU  - Mut-Salud, Nuria
AU  - Cruz-Bustos, Teresa
AU  - Gomez-Samblas, Mercedes
AU  - Carrasco, Esther
AU  - Garrido, Jose Manuel
AU  - López-Jaramillo, F Javier
AU  - Santoyo-Gonzalez, Francisco
AU  - Osuna, Antonio
PY  - 2016
DO  - 10.2147/IJN.S112560
UR  - http://hdl.handle.net/10668/10500
T2  - International journal of nanomedicine
AB  - Around 20%-30% of breast cancers overexpress the proto-oncogene human epidermal growth receptor 2 (HER2), and they are characterized by being very invasive. Therefore, many current studies are focused on testing new therapies against tumors that...
LA  - en
KW  - HER2
KW  - doxorubicin
KW  - nanoparticle
KW  - paclitaxel
KW  - protein A
KW  - targeted drug delivery
KW  - trastuzumab
KW  - Antineoplastic Agents
KW  - Breast Neoplasms
KW  - Cell Death
KW  - Cell Line, Tumor
KW  - Cell Survival
KW  - Doxorubicin
KW  - Drug Delivery Systems
KW  - Drug Resistance, Neoplasm
KW  - Endocytosis
KW  - Female
KW  - Flow Cytometry
KW  - Humans
KW  - ISCOMs
KW  - Lipids
KW  - MCF-7 Cells
KW  - Nanoparticles
KW  - Oxazines
KW  - Paclitaxel
KW  - Proto-Oncogene Mas
KW  - Receptor, ErbB-2
KW  - Staphylococcal Protein A
KW  - Sulfones
KW  - Trastuzumab
TI  - Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
TY  - research article
VL  - 11
ER  -